The United Kingdom and the United States have forged a important trade agreement that will ensure no levies on UK medicine products entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to increase funding on drugs through the public health system. This commitment guarantees that duties on these vital goods will be held at zero for a timeframe of 36 months.
This deal comes after recent statements to dramatically increase duties on patented pharmaceutical products, with figures floated as high as double the cost.
"This agreement with the UK bolsters the worldwide climate for innovative medicines and brings much-needed balance to transatlantic pharmaceutical trade," an announcement said.
Economic Importance
Medicines constitute one of the the United Kingdom's largest exports to the United States, which is easily the primary market for major UK drugmakers.
Trade data show that in the one-year period to the end of the third quarter, the UK sold medicines valued at £11.1bn to the US. This value represented nearly one-fifth of total UK exports in that span.
"This agreement protects employment, stimulates funding and sets the stage for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to increase total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Industry Background
This agreement follows a protracted row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were heightened by assertions that US customers were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or cancelled, while major investments have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
